Taysha Gene Therapies
On a mission to eradicate monogenic CNS disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $200m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 518 % | (46 %) | (14 %) | (32 %) | 1224 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (5028 %) | (440 %) | (998 %) | (1490 %) | (2609 %) | 127 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (6635 %) | (722 %) | (1072 %) | (1469 %) | (2513 %) | (134 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 3644 % | 367 % | 792 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Taysha Gene Therapies is a clinical-stage biotechnology company that focuses on developing and commercializing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). The company is dedicated to eradicating or treating severe and life-threatening monogenic diseases affecting the CNS.
As a clinical-stage company, Taysha Gene Therapies is actively engaged in clinical trials to test the safety and efficacy of its therapeutic candidates. The company's business model is centered on the research and development of these gene therapies, with the ultimate goal of obtaining regulatory approval and bringing them to market. Its primary clients are patients suffering from these rare and severe neurological conditions. The company operates in the biotechnology and pharmaceutical market, a highly regulated and competitive industry.
Keywords: gene therapy, biotechnology, clinical-stage, monogenic diseases, central nervous system, AAV-based therapies, rare diseases, neurological conditions, pharmaceutical, life sciences